Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $132.67 Consensus PT from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has received a consensus rating of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $132.67.

Several equities analysts recently weighed in on the company. Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently made changes to their positions in LNTH. Janus Henderson Group PLC grew its position in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. TD Asset Management Inc lifted its holdings in Lantheus by 1,028.0% in the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock valued at $66,623,000 after acquiring an additional 622,100 shares during the last quarter. Nuveen LLC acquired a new position in Lantheus in the first quarter valued at approximately $55,941,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Shares of Lantheus stock traded down $0.01 on Friday, hitting $77.82. The company's stock had a trading volume of 809,855 shares, compared to its average volume of 1,012,710. Lantheus has a 1 year low of $73.11 and a 1 year high of $126.89. The firm has a fifty day moving average price of $88.50 and a 200-day moving average price of $91.32. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 12.95 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the prior year, the firm earned $1.69 EPS. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. As a group, analysts forecast that Lantheus will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.